Property of Presenter. Not for Reproduction DENVER TB COURSE: CHALLENGING CLINICAL PRESENTATIONS
|
|
- Rhoda Cain
- 5 years ago
- Views:
Transcription
1 DENVER TB COURSE: CHALLENGING CLINICAL PRESENTATIONS Michelle Haas, M.D. Associate Director Denver Metro Tuberculosis Program Denver Public Health
2 DISCLOSURES No relevant financial relationships
3 OBJECTIVES Discuss challenging clinical presentations Identify comorbid conditions that affect TB management Review how active TB might have been prevented Review how delays in diagnosis can be minimized
4 57 year old man with DM, ESRD and coronary artery disease PATIENT 1 Grew up in Vietnam, moved to the US at the age of 40 +TST, no latent TB (LTBI) therapy recommended At pre-transplant evaluation: denies diagnosis of TB No further diagnostic evaluation or treatment
5 Several months later, he undergoes renal transplant PATIENT 1 New pleural effusion noted, attributed to volume overload No thoracentesis performed Day of renal transplant
6 PATIENT 1: HISTORY CONTINUED 5 months later admitted for cough, subjective fevers Pleural effusion, 149 cells 88% lymphocytes: Protein ratio 0.92 LDH ratio 0.6 Labelled as transudative effusion Bacterial, fungal and AFB cultures sent Treated for healthcare associated pneumonia
7 PATIENT 1: HISTORY CONTINUED Presented to care 10 days later with worsening symptoms Pleural fluid grew M. tuberculosis on day 22 IGRA+ AFB smears positive Current immunosuppressive regimen contains: Tacrolimus Mycophenolate mofetil Prednisone
8 QUESTIONS How could his active TB have been prevented? Identification of the diagnosis of latent TB and offering treatment for LTBI Very high risk for progression to active disease: Lived as a child in an area of high TB risk Diabetes ESRD What are the drug interactions to consider?
9 DRUG INTERACTIONS Immunosuppressive medication TB medication Interaction Tacrolimus Rifampin efficacy of tacrolimus Tacrolimus Optimal regimen (assuming drug-susceptible disease): Isoniazid Rifabutin Pyrazinamide Ethambutol Rifabutin efficacy of tacrolimus, less than rifampin Prednisone Rifampin efficacy of prednisone mycophenolate mofetil Rifampin efficacy of mycophenolate mofetil
10 WHAT IS THE OPTIMAL DURATION OF TB TREATMENT IN SOLID ORGAN TRANSPLANT PATIENTS No consensus regarding optimal duration One case series recommended months Case series from Spain: 10 months, 86% success rate Case series from France: 12 months, 10% without rifampin Median treatment time of 9 months with pyrazinamide and rifampin containing regimen Data on relapse is limited: 1/15 cases after 9 months of treatment at 3 years (Taiwan) 8.1% with treatment failure in French cohort Hsu, MS et al. The American Journal of the Medical Sciences, 2007; 334 (2) Munoz P, et al. Clin Infect Dis 2005;40:581 7 Garcia-Goez, JF, et al. Transplantation Proceedings, 41, (2009) Canet, E. Nephrol Dial Transplant (2011) 26:
11 TB IN RENAL TRANSPLANT Risk of TB substantially higher than in the general population Estimated at 250/100,000 when US incidence was 7/100,000 Mortality varies widely 6-30% Risk of graft rejection Disseminated disease in up to 27% Median time from transplant to development 9 months 1/3 within 12 months s/p transplant Klote M, et al. American Journal of Transplantation 2004; 4: Hsu, MS et al. The American Journal of the Medical Sciences, 2007; 334 (2) Canet E. Nephrol Dial Transplant (2011) 26:
12 PATIENT 1: CONTINUED 4 months into therapy Failure to regain weight Elevated LFTs Develops right sided chest pain and nodular density along right chest wall Eventually re-admitted
13 PATIENT 1: CONTINUED Undergoes thoracotomy with creation of an Eloesser flap for an empyema necessitans Repeat cultures for M. tuberculosis were negative Discharged on isoniazid and rifabutin Patient does not disclose he was discharged on TB medications Discovered during a clinic visit review of medications that he brought in from home
14 PATIENT 1: CONTINUED Finally gaining weight after Eloesser flap and clinically improving Successfully completed 9 months of treatment Will monitor closely for signs of relapse Eventually will go for Eloesser flap closure
15 LESSONS LEARNED Renal transplant clinic developing protocol to ensure all patients at risk for TB infection are screened Treatment of LTBI prior to transplant Additional hospital protocols in place to improve infection control Discussions with hospitalists about avoiding discharging patients with TB medications
16 SUMMARY Individuals who are immunocompromised are at risk for progression of disease Co-morbid conditions such as HIV and solid organ transplantation can complicate TB management Clinical suspicion for TB should remain high if no alternative diagnosis found Continued respiratory isolation Empiric treatment
17 HPI 60 year old man with cryptogenic cirrhosis, associated TIPS placement is admitted with fevers, cough, a chronic right sided effusion and decompensated cirrhosis (MELD 24) Started on vancomycin and cefepime for presumed HCAP New murmur identified, TTE with possible mitral valve vegetation Multiple blood cultures negative ID consulted to assist with the evaluation of culture negative endocarditis 2017 Denver Public Health
18 HPI Lived in Mexico as a child but has been living in the US for 18 years Prior admission 2 months before with sepsis and pneumonia. Found to have exudative pleural fluid, negative bacterial cultures Remote history of presenting to TB clinic several years prior, IGRA testing done at that time was negative 2017 Denver Public Health
19 6 MONTHS PRIOR DURING AN EPISODE OF GI BLEEDING HPI ADMISSION TWO MONTHS AGO WITH SEPSIS
20 Pleural fluid RBC 48,000 WBC 1,800 (73% L) Prot 2.2 LDH 279 (serum 422) Procalcitonin < 0.05 Discharged on Levofloxacin, symptoms improve HPI
21 ONE MONTH AFTER SEPSIS EPISODE HPI THIS ADMISSION
22 Pleural fluid current admission ph 7.35 Gluc 138 RBC 46,000 WBC 1,749 (78% L) Prot 2.5 (serum 4.5) LDH 215 (serum 421) ADA 2.1 (<9.4 normal) HPI AFB cultures not sent on pleural fluid
23 CBC WBC 3.0 Hct 24.8 Platelets 68 INR 2.5 Cr 0.94 HPI CONTINUED LFTs Total Bilirubin 5.0, direct 2.0 AST 50 ALT 28 Alb 1.2 Sputum 1+ AFB; Xpert (+) TB and Rifampin resistant
24 WHAT REGIMEN WOULD YOU RECOMMEND? Any additional testing? 2017 Denver Public Health
25 HPI Treatment started with levofloxacin, amikacin, EMB, linezolid and imipenem Imipenem discontinued after two weeks QTc stable at 500 MDDR-no INH resistance, confirmed rifampin resistance Phenotypic susceptibilities rifampin and pyrazinamide resistance 2017 Denver Public Health
26 CLINICAL COURSE Treatment Regimen Notes 4 weeks Levofloxacin, ethambutol, amikacin, linezolid converts cultures at one month treatment held 2 weeks developed perforated duodenum; AKI 6 weeks Levofloxacin, ethambutol restarted followed by amikacin Tolerates this well for some time; plan was to eventually stop amikacin and start linezolid 8-10 weeks 10 weeks Levofloxacin, ethambutol, amikacin TIW, linezolid TIW Levofloxacin, ethambutol, amikacin TIW bili of 12, mostly indirect, HCT 24 to19, evidence of hemolysis. Platelets decrease to 18. Linezolid felt to be contributing to anemia and thrombocytopenia 12 weeks Levofloxacin, ethambutol, amikacin TIW need for other agents? 2017 Denver Public Health
27
28 CLINICAL COURSE treatment regimen notes 14 weeks Levofloxacin, ethambutol, amikacin, added clofazimine weeks weeks Levofloxacin, ethambutol, clofazimine Levofloxacin, ethambutol, clofazimine Stopped amikacin at 15 weeks Develops right shoulder pain; reduced dose of levofloxacin to 500 mg; full thickness tear of supraspinatus tendon Worsening hepatohydrothorax, ascites and anasarca, estimated 40% mortality in 3 months (MELD 30); re-admitted 2017 Denver Public Health
29 CLINICAL COURSE AND OUTCOME Chooses hospice Died 30 weeks into treatment 2017 Denver Public Health
30 SUMMARY Treatment of drug-resistant TB in the context of cirrhosis is complex Limited treatment options Significant complications 2017 Denver Public Health
31 PATIENT # 2
32 HPI 49 year old man with newly diagnosed type II diabetes who presented to an outside hospital with back pain and numbness/tingling in his legs bilaterally No fever/chills No weight loss Vitals stable, afebrile Exam without neurologic deficits
33 MRI report: - likely metastatic disease - Pathologic 80% vertebral body fracture at T3, masslike lesion with epidural extension of presumed tumor and retropulsion severe canal stenosis
34 HPI
35 HPI Lived for years in Mexico, has been in the US since 2003 No health insurance TST reportedly negative; HIV negative Underwent biopsy of T3: Fibroadipose tissue and fragments of bone with prominent granulomatous inflammation No evidence of malignancy, no AFB or fungal organisms Discharged home on the following: Dexamethasone Metformin
36 Presents again 3 weeks later with: Continued numbness and tingling of the entire bilateral LE's as well as unsteady gait Worsening right sided upper back pain IGRA positive PSA 4.76 (>4 abnormal) HPI
37 HPI Transferred to a referral center and admitted to neurosurgery Underwent debulking with T3 corpectomy, T1- T5 spinal fusion, T2-4 decompression Concern for malignancy, PET scan ordered
38 Intense FDG activity in the following: Soft tissues around the site of the T3 corpectomy Left lateral sixth rib lesion with likely pathologic fracture Prostate Right scrotum CLINICAL COURSE
39 DISCUSSION POINTS Are PET scan findings more consistent with metastatic cancer, TB or both? Is granulomatous inflammation enough to start active TB treatment in the context of a positive IGRA?
40 Excisional biopsy of left rib mass, and fluid sampling for culture Blood and fibroadipose tissue. 2 nd Rib biopsy: Bone and bone marrow with extensive infiltration by non-caseating granulomas - No mycobacterial or fungal elements noted by AFB and GMS staining CLINICAL COURSE Prostate, right medial, right lateral, left medial and left lateral core biopsies: Benign prostatic tissue with acute and chronic inflammation, foreign body giant cell reaction and abundant noncaseating granulomas
41 CLINICAL COURSE Patient was initiated on isoniazid, rifampin, pyrazinamide and ethambutol PCR for Mycobacterium tuberculosis (Mtb) was positive from spinal mass/abscess fluid a few days later. Culture positive, pan-susceptible Rib biopsy cultures negative for Mtb Urine culture negative for Mtb Sputum cultures negative for Mtb
42 COULD HIS ACTIVE TB BEEN PREVENTED? Meets criteria for TB preventative screening with IGRA: From Mexico Has uncontrolled diabetes Had been in the US for 14 years prior to developing active TB Possible barriers: Lack of health insurance leading to challenges in receiving preventative care
43 SUMMARY Substantial overlap in the presentation of TB masquerading as metastatic disease PET scan and MRI imaging was interpreted as consistent with metastatic disease Biopsy of concerning lesions with findings clearly consistent with Mtb and not malignancy Delay in initiation of TB treatment related to substantial overlap in presentation with metastatic cancer Access to TB screening and treatment several years ago may have prevented him from developing active TB
My heart is racing. Managing Complex Cases. Case 1. Case 1
Managing Complex Cases My heart is racing Amee Patrawalla, MD April 7, 2017 Case 1 Rutgers, The State University of New Jersey Rutgers, The State University of New Jersey Case 1 29 year old physician from
More informationAnalysis. Answers. Action. Saturday Night Fever. Shaka Brown Capital Congress
Saturday Night Fever Shaka Brown Capital Congress Shaka Zulu October 31, 2012 SICK SUCKS How my illness started October 2013 August to October 2013 Symptoms: Severe fatigue Night sweats Low grade fever
More informationDiagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
More informationTB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012
TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release
More informationTB and Comorbidities Adriana Vasquez, MD April 12, 2018
TB and Comorbidities Adriana Vasquez, MD April 12, 2018 TB Nurse Case Management April 10 12, 2018 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Adriana Vasquez, MD has the following disclosures to make:
More informationTips and Tricks for Diagnosing and Treating Tuberculosis
Tips and Tricks for Diagnosing and Treating Tuberculosis Bob Belknap M.D. Director, Denver Metro TB Program December 6, 2017 DenverPublicHealth.org @DenverPublicHealth @DenPublicHealth Disclosures No conflicts
More informationRecognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016
Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the
More informationNorthwestern Polytechnic University
Clinical Tuberculosis Assessment by Health Care Provider Clinicians should review and verify the information in the Tuberculosis (TB) Screening Questionnaire (attached). Persons answering YES to any questions
More informationErrors in Dx and Rx of TB
Errors in Dx and Rx of TB David Schlossberg, MD, FACP Professor of Medicine Temple University School of Medicine Medical Director, TB Control Program Philadelphia Department of Public Health TB Still a
More informationTreatment of Tuberculosis
TB Clinical i l Intensive Seattle Treatment of Tuberculosis June 16, 2016 Masa Narita, MD Public Health Seattle & King County; Firland Northwest TB Center, University of Washington Outline Unique features
More informationTuberculosis Tools: A Clinical Update
Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary
More informationSevere β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy
Recommended Empirical Antibiotic Regimens for MICU Patients Notes: The antibiotic regimens shown are general guidelines and should not replace clinical judgment. Always assess for antibiotic allergies.
More informationThe Next 65 years: TB Technology and Innovation. Bob Belknap M.D. Director, Denver Metro TB Program
The Next 65 years: TB Technology and Innovation Bob Belknap M.D. Director, Denver Metro TB Program Disclosures 1. CDC funding for TBTC and TBESC 2. No conflicts of interest Objectives After the talk, you
More informationAnti Tuberculosis Medications: Side Effects & adverse Events
Anti Tuberculosis Medications: Side Effects & adverse Events Diana Fortune, RN, BSN September 13, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Diana Fortune, RN,
More informationManagement of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore
Management of MDR TB Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore Outline Global epidemiology of Tuberculosis Epidemiology of Tuberculosis
More information6/8/2018 TB TREATMENT. Bijan Ghassemieh, MD Seattle TB Clinical Intensive Disclosures. None
TB TREATMENT Bijan Ghassemieh, MD Seattle TB Clinical Intensive 2018 Disclosures None 1 Objectives Understand the following Rationale and goals for standard TB regimen When to initiate TB treatment Standard
More informationPatient History 1. Patient History 2. Social History. The Role of Surgery in the Management of TB. Reynard McDonald, MD & Paul Bolanowski, MD
Patient History 1 The Role of Surgery in the Management of TB Reynard McDonald, MD & Paul Bolanowski, MD September 16, 2010 42 y/o AA male was initially diagnosed with pansensitive pulmonary TB in 1986
More informationRehuka Khurana, MD, MPH has the following disclosures to make:
Case Presentation Steps to a Systematic Approach to Diagnosis of TB Case Presentation Steps to a Systematic Approach to Diagnosis of TB Renuka Khurana, MD, MPH March 13, 2015 TB for Pulmonologist March
More informationDIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE
DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH Assistant Professor University of Texas Health Science Center Staff Physician, Texas Center for Infectious Diseases TB Nurse Case
More informationDiagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015
Diagnosis & Medical Case Management of TB Disease Lisa Armitige, MD, PhD October 22, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE
More informationTB Grand Rounds. Reynard McDonald, MD & Henry Fraimow, MD January 30, Outline
TB Grand Rounds Reynard McDonald, MD & Henry Fraimow, MD January 30, 2007 Outline Overview of 2006 ATS statement regarding hepatotoxicity of anti-tb therapy Case examples highlighting management of patients
More informationTreatment of Active Tuberculosis
Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest
More informationWhat you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014
What you need to know about diagnosing and treating TB: a preventable, fatal disease Bob Belknap M.D. Denver Public Health November 2014 The Critical First Step Consider TB in the Differential 1. Risks
More informationTB Nurse Case Management San Antonio, Texas April 9-11, 2013
TB Nurse Case Management San Antonio, Texas April 9-11, 2013 TB / Dose Counting Rachel Munoz, RN. TB Nurse Case Manager/Nurse Consultant Austin/Travis County Health Department April 10, 2013 Rachel Munoz,
More informationTuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant
Tuberculosis and Diabetes Mellitus Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant Learning Objectives Understand the impact of uncontrolled diabetes mellitus (DM) on TB infection
More informationResearch in Tuberculosis: Translation into Practice
Case History Research in Tuberculosis: Translation into Practice This is a 6-year6 year-old Bosnian male, who presented to ER with one-week history of fever and occasional vomiting. No cough, difficulty
More informationChapter 22. Pulmonary Infections
Chapter 22 Pulmonary Infections Objectives State the incidence of pneumonia in the United States and its economic impact. Discuss the current classification scheme for pneumonia and be able to define hospital-acquired
More informationTB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?
Those oral antibiotics are just not working! Inpatient Standards of Care & Discharge Planning S/He s in the Hospital: Now What Do I Do? Dana G. Kissner, MD TB Intensive Workshop, Lansing, MI 2012 Objectives:
More informationESCMID Online Lecture Library. by author
Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain DISCLOSURES I have no potential conflicts with
More informationAt the end of this session, participants will be able to:
Advanced Concepts in Pediatric TB: Treatment of Tuberculosis Disease Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [with help from Andrea Cruz, M.D.] Objectives At the end
More informationCase 1: Clinical Presentation
Impostors and Preconceived Notions: Lessons Learned in TB Diagnosis & Treatment Tuberculosis Nursing Workshop June 1, 2015 Christopher Spitters, MD, MPH Tuberculosis Clinic Public Health Seattle & King
More informationTuberculosis and Diabetes Dec. 10, 2009 Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 1 of 18
Screening, Diagnosis, and Treatment of TB in Persons with Diabetes Dean Schillinger, M.D. University of California San Francisco CA Diabetes Program Gisela Schecter, M.D., M.P.H. TB Control Branch CA Department
More informationhas the following disclosures to make:
CLINICAL DIAGNOSIS AND MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH September 22, 2015 TB Nurse Case Management September 22 24, 2015 San Antonio. TX EXCELLENCE EXPERTISE INNOVATION Annie Kizilbash
More information10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose
Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population
More informationManaging Complex TB Cases Diana M. Nilsen, MD, RN
Managing Complex TB Cases Diana M. Nilsen, MD, RN Director of Medical Affairs NYC Department of Health & Mental Hygiene Bureau of TB Control Case #1 You are managing a patient who was seen at a private
More informationFundamentals of Tuberculosis (TB)
TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported
More informationPediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017
Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following disclosures
More informationWhat you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2013
What you need to know about diagnosing and treating TB: a preventable, fatal disease Bob Belknap M.D. Denver Public Health November 2013 Case 1: 52 y/o male Born in the Pacific Islands; some travel in
More informationCase Study 2016 Wisconsin Mycobacteriology Laboratory Network Annual Conference November 17, 2016
Case Study 2016 Wisconsin Mycobacteriology Laboratory Network Annual Conference November 17, 2016 Raymond P. Podzorski, Ph.D, D(ABMM) St. Mary s Hospital Laboratory and Wisconsin Region SSMHealth 608-258-6393
More informationTuberculosis: A Provider s Guide to
Tuberculosis: A Provider s Guide to Diagnosis and Treatment of Active Tuberculosis (TB) Disease and Screening and Treatment of Latent Tuberculosis Infection (LTBI) Alameda County Health Care Services Agency
More informationTB Clinical Guidelines: Revision Highlights March 2014
TB Clinical Guidelines: Revision Highlights March 2014 AIR TRAVEL & TB CONTROL With respect to non-ambulance air travel of patients diagnosed with or suspected as having active Mycobacterium tuberculosis,
More informationAcute Cholangitis. Kelsey Knotts PharmD Candidate Class of 2016
Acute Cholangitis Kelsey Knotts PharmD Candidate Class of 2016 Learning Objectives 1. Describe the mechanism of the development of acute cholangitis 2. Identify common causative organisms in acute cholangitis
More informationDiagnosis and Medical Management of Latent TB Infection
Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,
More informationPre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI:
Pre-Treatment Evaluation Before initiating treatment for LTBI: Treatment of Latent TB Infection (LTBI) Amee Patrawalla, MD Associate Professor, New Jersey Medical School Attending Physician, NJMS Global
More informationCHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 TUBERCULOSIS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY GLOBAL EMERGENCY: * Tuberculosis kills 5,000 people a day! * 2.3 million die each year!
More informationTuberculosis (TB) and Infection Control PICNET Conference April 12, 2013
Tuberculosis (TB) and Infection Control PICNET Conference April 12, 2013 Michelle Mesaros RN BScN Nash Dhalla RN BScN BC Center for Disease Control TB and Infection Control WHAT IS TB? TB Statistics (2011)
More informationDiagnosing TB in HIV Co- infected PaAents
Diagnosing TB in HIV Co- infected PaAents Bob Belknap Denver Public Health Disclosures No financial disclosures slides adapted from Dr. Michelle Haas Session ObjecAves ParAcipants will be able to: 1. Reduce
More informationLTBI in Special Populations John Nava, MD October 5, 2010
Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 LTBI in Special Populations John Nava, MD October 5, 2010 2 Treatment of Latent TB Infection in Special Populations John
More informationPneumonia Community-Acquired Healthcare-Associated
Pneumonia Community-Acquired Healthcare-Associated Edwin Yu Clin Infect Dis 2007;44(S2):27-72 Am J Respir Crit Care Med 2005; 171:388-416 IDSA / ATS Guidelines Microbiology Principles and Practice of Infectious
More informationMoving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 LTBI and TB Disease Treatment Cara Christ, MD, MS May 8, 2012 Cara Christ, MD, MS has the following disclosures to make: No conflict
More informationCase Presentations Part 2
Case Presentations Part 2 Connie A. Haley, MD MPH University of Florida, Infectious Diseases and Global Medicine Megan Ninneman, PA Jackson Memorial Hospital, Miami FL Objectives Demonstrate the ability
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Common disease presentations Diagnosis of active TB Screening
More informationMycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
More informationDiagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011 Lisa Armitige, MD, PhD has the following disclosures to make:
More informationTuberculosis Reporting, Waco-McLennan County Public Health District TB Control WMCPHD (254)
Tuberculosis Reporting, Waco-McLennan County Public Health District TB Control WMCPHD (254)-750-5496 Local health care providers, including physicians offices, labs and hospitals, are required by law to
More informationChapter 5 Treatment for Latent Tuberculosis Infection
Chapter 5 Treatment for Latent Tuberculosis Infection Table of Contents Chapter Objectives.... 109 Introduction.... 111 Candidates for the Treatment of LTBI... 112 LTBI Treatment Regimens.... 118 LTBI
More informationDrug Interactions Lisa Armitige, MD, PhD November 17, 2010
Substance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010 Drug Interactions Lisa Armitige, MD, PhD November 17, 2010 Drug Interactions Lisa Y. Armitige, M.D., Ph.D. Medical Consultant
More informationDebbie Onofre, RN, BSN March 18, TB Nurse Case Management March 17 19, 2015 San Antonio, Texas
Managing and Monitoring Side Effects and Toxicities of Anti TB Therapy Debbie Onofre, RN, BSN March 18, 2015 TB Nurse Case Management March 17 19, 2015 San Antonio, Texas EXCELLENCE EXPERTISE INNOVATION
More informationINDEX CASE INFORMATION
Instructions for Completing the MDH Tuberculosis Contact Investigation Report Form Please provide as much information as possible. Each field represents information that is important to the contact investigation.
More informationDiagnosis and Medical Management of TB Disease. Quratulian Annie Kizilbash, MD, MPH March 17, 2015
Diagnosis and Medical Management of TB Disease Quratulian Annie Kizilbash, MD, MPH March 17, 2015 TB Nurse Case Management March 17 19, 2015 San Antonio, Texas EXCELLENCE EXPERTISE INNOVATION Quratulian
More information3/25/2012. numerous micro-organismsorganisms
Congenital & Neonatal TB A Case of Tuberculosis Congenital or Acquired? Felicia Dworkin, MD NYC DOHMH Bureau TB Control World TB Day March 23, 2012 Congenital TB: acquired by the fetus during pregnancy
More information1 yr old girl presented with Fever on and off 3 months H/o frequent semisolid bulky stools 3 months Progressive abdominal distension 3 months Failure
Dr Rajasree S Dr Srinivas S, Dr Bagdi RK, Dr Satheesh C Apollo Childrens Hospital, Chennai 1 yr old girl presented with Fever on and off 3 months H/o frequent semisolid bulky stools 3 months Progressive
More informationTreatment of Tuberculosis Disease. Treatment of Tuberculosis. Decision to Treat Initiation of Therapy 1
Treatment of Tuberculosis Some Highlights of Most Recent Update Treatment of Tuberculosis Disease Germaine Jacquette, MD Physician Specialist NJMS Global Tuberculosis Institute September 15, 2010 The provider
More informationPediatric TB Radiology: It s Not Black and White Part 2
Experiencing technical difficulties? Please call Adobe Connect for technical assistance at 1-800-422-3623 Pediatric TB Radiology: It s Not Black and White Part 2 June 18, 2018 A National Webinar June 18,
More informationPediatric TB Intensive Houston, Texas
Pediatric TB Intensive Houston, Texas November 13, 2009 Treatment of Pediatric TB Jeffrey R. Starke, M.D. November 13, 2009 MANAGEMENT OF CHILDHOOD TUBERCULOSIS Jeffrey R. Starke, M.D. Professor of Pediatrics
More informationPediatric TB Lisa Armitige, MD, PhD September 28, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Pediatric TB Lisa Armitige, MD, PhD September 28, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interest.
More informationTB Intensive Houston, Texas. Childhood Tuberculosis Kim Connelly Smith. November 12, 2009
TB Intensive Houston, Texas November 10-12, 12 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 1 OUTLINE Stages
More informationCase presentation. Dr Connie Haley, MD, MPH Dr Gautam Kalyatanda, MD
Case presentation Dr Connie Haley, MD, MPH Dr Gautam Kalyatanda, MD History of presenting illness 20 Year old woman from Nigeria who came to study at Montgomery in August 2013 About 2 weeks after arriving,
More informationTB Nurse Case Management San Antonio, TX. TB Medications and Adverse Effects
TB Nurse Case Management San Antonio, TX April 1 3, 2014 TB Medications and Adverse Effects Debbie Onofre RN, BSN Nurse Consultant/ Nurse Educator Heartland National TB Center April 1, 2014 Debbie Onofre,
More informationTB in the Patient with HIV
TB in the Patient with HIV Lisa Y. Armitige, MD, PhD May 11, 2017 TB Intensive May 9 12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD, has the following disclosures to
More informationTB Intensive San Antonio, Texas May 7-10, 2013
TB Intensive San Antonio, Texas May 7-10, 2013 TB in the HIV Patient Lisa Armitige, MD, PhD May 09, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant
More informationTreatment and Monitoring
Treatment and Monitoring Disclosures We have no actual or potential conflicts of interest in relation to this presentations. We have no financial relationships to disclose. Learning Objectives After this
More informationTuberculosis in the Traveler
Tuberculosis in the Traveler Waterloo-Wellington Cardiovascular Respiratory Conference April 27 th, 2016 The Beat on Breathing Watch, Treat or Admit? disclosures No Potential for conflict of interest Staffed
More informationTuberculosis: update 2013
Tuberculosis: update 2013 William R. Bishai, MD, PhD Center for TB Research Division of Infectious Diseases Department of Medicine Johns Hopkins School of Medicine Question 1 A TB speaker at a major conference
More informationTB in Corrections Phoenix, Arizona
TB in Corrections Phoenix, Arizona March 24, 2011 Treatment of Latent TB Infection Renuka Khurana MD, MPH March 24, 2011 Renuka Khurana, MD, MPH has the following disclosures to make: No conflict of interests
More informationScreening and Treatment Recommendations for Persons Exposed to MDR TB
Screening and Treatment Recommendations for Persons Exposed to MDR TB Although all persons at increased risk of tuberculosis (TB) infection should be screened for TB infection per USPTF/CDC guidelines
More informationCase Management of the TB/HIV Infected Patient
TB Nurse Case Management San Antonio, Texas December 8-10, 2009 Case Management of the TB/HIV Infected Patient Sarah Hoffman, MPH, MSN, ACRN December 9, 2009 TB/HIV: Considerations in the Care of the Coinfected
More informationSouth African HIV Clinicians Society Managing adult treatment through case study discussion
South African HIV Clinicians Society Managing adult treatment through case study discussion Jade Mogambery Grey s Hospital, Pietermaritzburg Infectious Diseases Unit Referral summary 20-year-old male HIV
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
PAGE 1 of 7 References Related ACA Standards 4 th Edition Standards for Adult Correctional Institutions 4-4350, 4-4355 These guidelines are based on the recommendations of the American Thoracic Society
More information8/11/2015. Febrile neutropenia Bone marrow transplant Immunosuppressant medications
Dean Van Loo Pharm.D. Febrile neutropenia Bone marrow transplant Immunosuppressant medications Steroids Biologics Antineoplastic Most data from cancer chemotherapy Bone marrow suppression Fever is the
More informationCase 1. Background. Presenting Symptoms. Schecter Case1 Differential Diagnosis of TB 1
TB or Not TB? Case 1 Gisela Schecter, M.D., M.P.H. California Department of Public Health Background 26 year old African American male Born and raised in Bay Area of California Convicted of cocaine trafficking
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Microbiology Epidemiology Common disease presentations Diagnosis of active
More informationTB in Prisons and Jails Albuquerque, New Mexico November 28, 2012
TB in Prisons and Jails Albuquerque, New Mexico November 28, 2012 Challenges of TB Treatment in Special Populations in Corrections Marcos Burgos, MD November 28, 2012 Marcos Burgos, MD has the following
More informationSA TB Guidelines The interface with Advanced Clinical Care
SA TB Guidelines The interface with Advanced Clinical Care Dr Kogie Naidoo (MBCHB, PHD) Head: CAPRISA Treatment Research Programme Honorary Lecturer - UKZN Department of Public Heath Medicine Annual Workshop
More informationCase presentation. Dr REESAUL R
Case presentation Dr REESAUL R Mr S. 25 years old Case 1 Ref on 06/ April /2006 to Chest Clinic from a private GP of Port Louis for : Cough + haemoptysis and dyspnoea Case 1(6/April/2006) Mr S Single 25
More information8/28/2017. Learning Objectives. After attending this presentation, learners will be able to:
New and Noteworthy in Tuberculosis Diagnostics and Treatment Susan Swindells, MBBS Professor of Internal Medicine University of Nebraska Medical Center Omaha, Nebraska San Antonio, Texas: August 21 to
More informationExtrapulmonary Tuberculosis
Extrapulmonary Tuberculosis Timothy H. Dellit, MD Professor, UW Allergy & Infectious Diseases Associate Medical Director Harborview Medical Center No financial conflicts Tuberculosis in King County1995-2014
More informationTuberculosis Intensive
Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 TB in the HIV Patient Lisa Armitige, MD, PhD April 6, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests
More informationCardiovascular Center Grand Rounds. December 15, 2016
Cardiovascular Center Grand Rounds December 15, 2016 Agenda Overview of Heater-Cooler Device Issue NTM Infection Incidence Chronology of Events and Communications Risk Management Implications Q&A NTM Grand
More informationTreating TB What Happened? All the Patients Have Challenging Co-Morbid Conditions Now!
EXCELLENCE EXPERTISE INNOVATION Treating TB What Happened? All the Patients Have Challenging Co-Morbid Conditions Now! Barbara J Seaworth, MD, Medical Director, Heartland National TB Center Professor,
More informationThe Elimination of Tuberculosis. Richard E. Chaisson, MD. Center for TB Research Center for AIDS Research Johns Hopkins University
The Elimination of Tuberculosis Richard E. Chaisson, MD Center for TB Research Center for AIDS Research Johns Hopkins University Disclosures Spouse owns Merck stock Consultant: Merck Research funding:
More informationMycobacteria Diagnostic Testing in Manitoba. Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline
Mycobacteria Diagnostic Testing in Manitoba Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline Acknowlegements: Assunta Rendina: Charge Tech HSC Lab Joyce Wolf & Dr. Meenu Sharma: NML Dr. Kanchana
More informationManagement of Drug-resistant Tuberculosis (DR-TB)
Management of Drug-resistant Tuberculosis (DR-TB) Nitipatana Chierakul Division of Respiratory Disease & Tuberculosis Department of Medicine Faculty of Medicine Siriraj Hospital October 14 th, 2008 Tropical
More informationKen Jost, BA, has the following disclosures to make:
Diagnosis of TB Disease: Laboratory Ken Jost, BA May 10, 2017 TB Intensive May 9-12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Ken Jost, BA, has the following disclosures to make: No conflict
More informationTB Nurse Case Management San Antonio, Texas July 18 20, 2012
TB Nurse Case Management San Antonio, Texas July 18 20, 2012 Pediatric TB Kim Smith, MD, MPH July 19, 2012 Kim Smith, MD, MPH has the following disclosures to make: No conflict of interests No relevant
More informationTuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013
Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013 1 TB in Toronto - risk groups Diagnosis of active TB LTBI diagnosis and management Infection control 2 TB in Toronto Case
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Extrapulmonary TB Linda Dooley, MD November 13, 2014 Linda Dooley, MD has the following disclosures to make: No conflict of interests No relevant financial
More information2016 Annual Tuberculosis Report For Fresno County
206 Annual Tuberculosis Report For Fresno County Cases Rate per 00,000 people 206 Tuberculosis Annual Report Fresno County Department of Public Health (FCDPH) Tuberculosis Control Program Tuberculosis
More informationFailure to Implement the Plan to Eliminate TB in the US: Implications in the Era of Declining Resources
Failure to Implement the Plan to Eliminate TB in the US: Implications in the Era of Declining Resources Sustaining Public Health Capacity in an Age of Austerity Forum on Microbial Threats Board on Global
More informationManagement of MDR TB in special situations. Dr Sarabjit Chadha The Union
Management of MDR TB in special situations Dr Sarabjit Chadha The Union MDR TB in special situations Pregnancy Breastfeeding Contraception Renal Insufficiency Diabetes Pregnancy and TB Pregnancy is not
More information